ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-129.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -38.79% |
| Return on Assets (Trailing 12 Months) | -36.22% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.47 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.52 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 100.36M |
| Free Float | 93.51M |
| Market Capitalization | $1.36B |
| Average Volume (Last 20 Days) | 1.44M |
| Beta (Past 60 Months) | 1.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.82% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |